Asset
INETAGUGENE GEPERPAVEC
Krystal Biotech Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04047732 | phase1_2 | unknown | 2019-08-27 | 2022-10-01 | Krystal Biotech, Inc. | Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) |
| NCT05735158 | phase2 | unknown | 2023-03-01 | 2024-03-01 | Krystal Biotech, Inc. | Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) |
FDA applications (0)
This company has no applications containing this asset.